Plain-English translation of NCT04606914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called mirvetuximab soravtansine, combined with the chemotherapy drug carboplatin, to treat advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication works by targeting a specific protein (folate receptor alpha) that is often found on cancer cells but rarely on healthy tissue. Researchers believe this targeted approach may help fight these cancers more effectively when given before surgery.
Ovarian cancer remains very serious, with low survival rates despite standard chemotherapy. This trial exists because researchers want to see if adding this new targeted medication to traditional chemotherapy can improve outcomes for patients whose cancer cells have the folate receptor alpha protein.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive 7 cycles of carboplatin (given intravenously every 3 weeks), with the new medication added starting in the second cycle and continuing for 6 cycles. The first cycle will be carboplatin alone to see how your body tolerates it. You will have regular blood tests and clinic visits to monitor how you're tolerating the treatment. The goal is to shrink your cancer before you undergo surgery.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States